[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Universidade Nova de Lisboa\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":297},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,49,73,96,124,145,166,192,224,252,268],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":4},"100641423","platelet-rich-plasma-for-partial-rotator-cuff-tears-100641423",false,"NCT07659600","Platelet-Rich Plasma for Partial Rotator Cuff Tears","Performance of Autologous Platelet-rich Plasma Injection for Tendon Regeneration in Partial Supraspinatus Tears","OPTIMISE","Inclusion Criteria:\n\n* Eligible patients are at least 18 years old, and have clinical (VAS pain score ≥4, loss of \\>25% in ROM, positive in at least one clinical test such as Jobe, Neer, Drop arm, Hawins-Kennedy, Patte) and imaging findings compatible with partial supraspinatus tear, within 3 months of diagnosis.\n* Patients may have undergone conservative treatments, including lifestyle modification, oral analgesics, or physical therapy, with the exception of shoulder injections.\n* Must be willing to provide consent.\n\nExclusion Criteria:\n\n* Patients less than 18 years old\n* Patients with other or concomitant rotator cuff or shoulder muscle\u002Ftendon tear(s), complete tears, SLAP tears ≥ grade 2\n* Patients with auto-immune based joint diseases, osteoarthritis (KL grade ≥ 2), adhesive capsulitis, infection, nerve-related conditions, immunocompromised conditions, malignancy, coagulopathy\n* Patients on antiplatelet, anticoagulant, antitumor or immunosuppressive drugs\n* Uncontrolled diabetes, other systemic disorders (hepatitis, rheumatoid arthritis)\n* Pregnancy\n* Shoulder instability\n* Previous shoulder injection or surgery\n* Unwillingness to provide informed consent","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn whether platelet-rich plasma (PRP) injection, made from a participant's own blood, can help heal the tendon and improve shoulder symptoms in people with partial tears of the supraspinatus tendon.\n\nThe main questions it aims to answer are:\n\n* Does PRP help the tendon heal?\n* Does PRP improve pain, shoulder movement, daily function, and shoulder magnetic resonance imaging (MRI) findings?\n\nResearchers will compare PRP plus standard of care (physical therapy) to standard of care alone to see if PRP leads to better healing and better clinical results. Researchers will also study if differences in specific biomolecules in PRP are associated with differences in treatment response.\n\nParticipants will:\n\n* receive standard of care treatment, with or without PRP injection depending on the study group\n* have blood collected for PRP preparation\n* have their pain, shoulder movement, and shoulder function assessed\n* undergo shoulder MRI scans\n* be followed over time to measure healing and symptom improvement",[27,28,29],"Partial Supraspinatus Tear","Rotator Cuff Tears (RCTs)","Rotator Cuff Injury",[31,32,33,34,35,36],"Platelet-Rich Plasma","Partial Supraspinatus Tears","Rotator Cuff Tears","Autologous PRP","PRP","Shoulder pain","NOT_YET_RECRUITING","2026-06-15",{"date":40,"type":41},"2026-06-22","ACTUAL",{"date":43,"type":21},"2026-06-01",{"date":45,"type":21},"2029-12-01",{"name":47,"class":48},"Universidade Nova de Lisboa","OTHER",{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":59,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100638915","clinical-study-to-identify-biomarkers-for-tumor-spread-through-air-spaces-status-100638915","NCT07630246","CLINICAL STUDY TO IDENTIFY BIOMARKERS FOR TUMOR SPREAD THROUGH AIR SPACES STATUS","UNCOVERING THE GENETIC LANDSCAPE OF LUNG ADENOCARCINOMA: A CLINICAL STUDY TO IDENTIFY BIOMARKERS FOR TUMOR SPREAD THROUGH AIR SPACES STATUS","PAIR-LUNG","Inclusion Criteria:\n\n* Patients older than 18 years old\n* Active early LUAD diagnosis according to the American Joint Committee on Cancer\n* Signed informed consent or previous consent given for future research\n\nExclusion Criteria:\n\n* History of inflammatory bowel disease and autoimmune diseases\n* History of hepatic disease (including history of alcoholic or viral hepatitis)\n* LUAD patients with other active malignancy(ies)\n* Previous treatment for LUAD\n* Incapability of understanding the study and\u002For providing consent\n* Signed informed consent unavailable",{"count":58,"type":21},140,"1 Year","OBSERVATIONAL","Lung cancer remains a significant challenge in oncology, with poor prognosis for patients, especially those with advanced-stage disease. The phenomenon of tumor spread through air spaces (STAS) in pulmonary cancer has garnered attention for its association with aggressive tumor behavior and adverse clinical outcomes. Spread through air spaces identification has been highly debatable on scientific community as an important prognostic feature for distant and locoregional recurrence and as a key player in the differential diagnosis and selection of the appropriate treatment. The aim of this study is to unravel the complexities of STAS-positive lung adenocarcinoma (LUAD) diagnosis and treatment options. For that, we intend to (1) isolate primary lung cancer tissues from early-stages lung adenocarcinoma to fabricate organoid in vitro models and (2) evaluate the microRNA (miRNA) profile of tumor and healthy tissue samples. This is a Hybrid (prospective and retrospective) observational clinical study with a nested translational study.",[63],"Lung Adenocarcinoma",[65],"Pulmonary cancer, Lung, Tumor spread through air spaces",{"date":67,"type":41},"2026-06-05",{"date":43,"type":21},{"date":70,"type":21},"2029-06-30",{"name":47,"class":48},2,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":79,"sex":17,"minAge":18,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},"100636041","impact-of-a-wheat-based-fermented-beverage-on-microbiota-and-metabolic-health-in-healthy-individuals-100636041","NCT07560527","Impact of a Wheat-based Fermented Beverage on Microbiota and Metabolic Health in Healthy Individuals","Inclusion Criteria:\n\n* Body Mass Index (BMI) between 18.5 and 24.9 kg\u002Fm²\n* Healthy status\n* Willingness to consume a fermented wheat-based beverage daily for 4 weeks\n* Capacity and willingness to provide written informed consent\n\nExclusion Criteria:\n\n* Use of antibiotics and\u002For probiotics in the 12 weeks prior to the study\n* Weight variation \\>10% within the last 3 months\n* Participation in any clinical study or trial within the previous 12 months\n* Diagnosed medical conditions, including: diabetes, liver disease (e.g., cirrhosis), pancreatitis or other malabsorption syndromes, gastrointestinal disorders (e.g., inflammatory bowel disease, celiac disease), history of weight-loss surgery (e.g., bariatric surgery), chronic respiratory, neurological, psychiatric, musculoskeletal, or other systemic conditions, eating disorders\n* Diagnosed food allergies or intolerances\n* Pregnancy or breastfeeding",true,"65 Years",{"count":82,"type":21},20,[24],"The proposed study aims to evaluate the impact on intestinal and oral microbiota composition and the metabolic effects of the daily consumption of a wheat-based fermented beverage, developed under the collaborative WHEATBIOME project, over a 4-week intervention period in healthy adults.",[86],"Health Adult Subjects","2026-04-27",{"date":89,"type":41},"2026-05-01",{"date":91,"type":21},"2026-05-20",{"date":93,"type":21},"2026-12-31",{"name":47,"class":48},1,{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":79,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":22,"phases":105,"briefSummary":106,"conditions":107,"keywords":111,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":95},"100614196","effectiveness-of-the-dmhi-and-ops-platform-in-improving-participant-qol-a-randomised-controlled-trial-100614196","NCT07276451","Effectiveness of the DMHI and OPS Platform in Improving Participant QOL: a Randomised Controlled Trial.","Effectiveness of the Digital Mental Health Intervention and Open Peer Support Platform in Improving Participant Quality of Life: a Randomised Controlled Trial.","Inclusion Criteria:\n\n* Aged ≥18 years;\n* No current clinical diagnosis of a mental health disorder;\n* No mental-health treatment or psychotropic medication initiated within the past 3 months;\n* Able to access the internet and provide informed consent.\n\nExclusion Criteria:\n\n* Current engagement with a mental health professional or therapy;\n* Inability to access the DMHI and OPS platform, or inability to provide informed consent;\n* PHQ-9 score ≥15 or GAD-7 score ≥15 at baseline (these participants will be referred to specialist services and excluded from further study participation)\n\nConfirmation of eligibility to participate. To comply with local regulations and ensure participant safety, a qualified and appropriately licensed specialist, affiliated with the institution will participate in screening of the participants recruitment results and carrying out decisions on whether to include or exclude the participant from the study based on degree of severity in the underlying psychological or psychiatric condition. The decision to exclude participants will be made based on safety considerations, need for emergency psychiatric help, compliance assumption and perceived efficacy.\n\nWithdrawal. Participation is voluntary. All enrolled participants are free to withdraw from the study at any time with or without notice to study personnel.\n\nRisk to self and\u002For others. During enrollment and study course, participants will be screened for severity of symptoms. If our participating specialist identifies a risk to self or others, appropriate actions will be taken to contact the authorities and local law representatives according to European and Local Law.\n\nSample size estimates. For two groups and a dichotomous endpoint (improvement or no improvement) and an anticipated incidence of 45% in the intervention group and 75% in the control group, at a 95% confidence level and 5% margin of error, power of 80% and enrolment ratio of 1, a sample size of 82 participants was chosen for this RCT (41 in intervention group, 41 in control group).",{"count":104,"type":21},82,[24],"RCT to evaluate the efficacy of a digital mental health intervention platform with open peer support in improving participant quality of life.",[108,109,110],"Anxiety","Depression and Quality of Life","Quality of Life",[112,113,114,115],"digital mental health intervention","open peer support","mental health","online support","2025-11-28",{"date":118,"type":41},"2025-12-11",{"date":120,"type":21},"2026-01-01",{"date":122,"type":21},"2026-09",{"name":47,"class":48},{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":79,"sex":17,"minAge":130,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":144,"locationsCount":95},"100541840","gait-analysis-and-degenerative-spine-100541840","NCT06335095","Gait Analysis and Degenerative Spine","Inclusion Criteria:\n\n* Age between 50 and 85 years\n* Diagnosis of spinal disease by clinical and imagiological criteria\n* More than 3 months duration of disease\n* Ability to give consent\n* Fluent portuguese speaker\n\nExclusion Criteria:\n\n* Previous spine surgery\n* Spinal instability\n* Neurological disease that might interfere with walking\n* Known orthopedic conditions that causes significant gait impairment\n* Dementia or development disorder with cognitive impairment\n* Inability to give consent","50 Years","85 Years",{"count":133,"type":21},200,"The goal of this observational study is to analyse the biomechanics of a degenerative spinal disease. The main questions it aims to answer are:\n\n* What are the biomechanical variables affected by the disease\n* How they evolve with disease progression and treatment",[136],"Spinal Disease","RECRUITING","2025-03-13",{"date":140,"type":41},"2025-03-19",{"date":142,"type":41},"2024-04-01",{"date":122,"type":21},{"name":47,"class":48},{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":79,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":22,"phases":154,"briefSummary":155,"conditions":156,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":95},"100577147","cgmp-metabolism-and-appetite-modulation-100577147","NCT06794515","cGMP: Metabolism and Appetite Modulation","Metabolic Effects of cGMP: From Amino Acid Absorption Kinetics to Appetite Modulation","Inclusion Criteria:\n\n* Men or women\n* Adults (age ≥ 18 years)\n* Body Mass Index (BMI) between 18.5-25.0 kg\u002Fm2\n* Filling informed consent\n\nExclusion Criteria:\n\n* Clinically significant illness\n* Have changed frequency, duration, or intensity of physical activity in the last month\n* Taking protein supplements\n* Pregnant or breastfeeding\n* Smoking and drug use",{"count":153,"type":21},15,[24],"Phenylketonuria is an inborn error of phenylalanine metabolism. Although the phenylalanine-restricted diet is recognized as the mainstay of therapy, little is known about the impact of protein substitutes on the metabolism of patients with phenylketonuria.\n\nTherefore, the aim of this project is to study the impact of acute ingestion of casein glycomacropeptide supplemented with amino acids (cCGMP-AAs) alone or in combination with two different meals on amino acid absorption kinetics, glycaemic and insulinemic response, and on acute markers of appetite control.\n\nThe main findings of this project will bring new insights into the dietary management of these patients, which may lead to improvements in protein substitutes formulations.",[157],"Healthy","2025-01-20",{"date":160,"type":41},"2025-01-27",{"date":162,"type":21},"2025-02-03",{"date":164,"type":21},"2025-04-24",{"name":47,"class":48},{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":79,"sex":17,"minAge":18,"maxAge":80,"enrollmentInfo":174,"targetDuration":176,"studyType":60,"phases":4,"briefSummary":177,"conditions":178,"keywords":182,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":95},"100575904","biomarkers-in-inflammatory-rheumatic-diseases-diagnosis-100575904","NCT06778343","Biomarkers in Inflammatory Rheumatic Diseases Diagnosis","BIRDD: Biomarkers in Inflammatory Rheumatic Diseases Diagnosis - Ankylosing Spondylitis, Rheumatoid Arthritis and Systemic Lupus Erythematosus","BIRDD","Inclusion Criteria:\n\n* Diagnosis of AS, RA, SLE according the mentioned criteria;\n* Ability to provide informed consent;\n* If entering the study on NSAIDs, tramadol, combination of paracetamol and codeine or hydrocodone, and\u002For non-opioid analgesics, subject must be on stable dose(s) for at least 14 days prior to the screening visit;\n* If entering the study on oral corticosteroids, subject must be on a stable dose of prednisone (≤ 10 mg\u002Fday), or oral corticosteroid equivalents, for at least 14 days prior to the screening visit;\n* If entering the study on MTX, leflunomide, SSZ, and\u002For hydroxychloroquine, subject must be on a stable dose of MTX (≤ 25 mg\u002Fweek) and\u002For SSZ (≤ 3 g\u002Fday) and\u002For hydroxychloroquine (≤ 400 mg\u002Fday) or leflunomide (≤ 20 mg\u002Fday) for at least 28 days prior to the screening visit. A combination of up to two background csDMARDs is allowed;\n* Subject is judged to be in good health as determined by the Principal Investigator based upon the results of medical history, laboratory profile, physical examination, x-Ray performed at the Screening Visit.\n\nExclusion Criteria:\n\n* Current pregnancy or breastfeeding;\n* Prior exposure to any biologic therapy;\n* Intra-articular joint or tendon sheaths injections, spinal\u002Fparaspinal injection(s), or parenteral administration of corticosteroids within 28 days prior to the Baseline Visit. Inhaled or topical corticosteroids are allowed;\n* Receipt of any live vaccine within 4 weeks prior to the screening visit;\n* History of clinically significant (per Investigator\\'s judgment) drug or alcohol abuse within the last 6 months;\n* Subject has a history of inflammatory arthritis of different etiology other than AS, RA or SLE (including but not limited to PsA, mixed connective tissue disease, reactive arthritis, scleroderma, polymyositis, dermatomyositis, fibromyalgia), or any arthritis with onset prior to 17 years of age;\n* Any uncontrolled medical condition (e.g., uncontrolled diabetes mellitus, unstable ischemic heart disease);\n* History of any malignancy;\n* Positive serology for hepatitis B, hepatitis C, or human immunodeficiency virus;\n* Infections requiring hospitalization or intravenous treatment with antibiotics within 30 days or oral treatment with antibiotics within 14 days before enrollment;\n* Note : Healthy Controls should be matched by gender and age. People with acute infections or injuries (in the last 6 months) or non-controlled chronic diseases (cardiac, metabolic, lung, neurologic, gastro-intestinal or renal) will be exclude. Family history of Auto-Immune diseases as diagnosed by a rheumatologist will be also excluded.",{"count":175,"type":21},134,"3 Months","Ankylosing spondylitis (AS), Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) are three diseases where early diagnosis remains a major challenge. However, early diagnosis is the main determinant for a better prognosis. In the early stage, symptoms may be nonspecific and often difficult to establish a differential diagnosis between rheumatic diseases and other diseases, namely infectious and cancer diseases.",[179,180,181],"Ankylosing Spondylitis","Rheumatic Arthritis","Systemic Lupus Erythematosus",[183,184],"Biomarker","Diagnosis","2025-01-16",{"date":158,"type":41},{"date":188,"type":41},"2023-01-31",{"date":190,"type":21},"2025-06-30",{"name":47,"class":48},{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":79,"sex":17,"minAge":18,"maxAge":200,"enrollmentInfo":201,"targetDuration":4,"studyType":22,"phases":203,"briefSummary":204,"conditions":205,"keywords":210,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":95},"100505258","metabolic-effects-of-bariatric-arterial-embolization-vs-bariatric-surgery-100505258","NCT05859022","Metabolic Effects of Bariatric Arterial Embolization vs Bariatric Surgery","Comparison of Metabolic Effects of Bariatric Arterial Embolization vs. Bariatric Surgery","BEOD","Inclusion Criteria:\n\n* criteria:\n\n  1. Is the candidate for general anesthesia.\n  2. Body Mass Index (BMI) between 33 and 43 Kg\u002Fm2\n  3. Patients have a biochemical evidence of Type 2 Diabetes Mellitus (DMT2) confirmed by American Diabetes Association (ADA) criteria:\n\n     3.1) treated - HbA1c 7,1%; 3.2) If untreated- fasting 2-hour plasma glucose level of 200 mg\u002FdL during an oral glucose tolerance test and a HbA1c of 7,1%.\n  4. Willing, able, and mentally competent to provide written informed consent.\n  5. Able o understand the options and to comply with the requirements of each program.\n  6. Have a negative urine pregnancy test at screening and baseline visits (prior surgery and Embolization) for women of childbearing potential.\n  7. Female patients must agree to use reliable method of contraception for 2 years.\n\nExclusion Criteria:\n\n1. Prior bariatric surgery of any kind.\n2. Prior complex abdominal surgery including splenectomy, upper GI, anti-reflux surgery and trauma.\n3. Abdominal, thoracic, pelvic and\u002For obstetric-gynaecologic surgery within 3 months or at the discretion of the surgery.\n4. Cardiovascular conditions including uncompensated congestive heart failure, dysrhythmia, history of stroke, or uncontrolled hypertension (defined as medically treated with the mean of 3 separate measurements systolic blood pressure (SBP)\\> 180 mmHg or diastolic blood pressure (DBP) \\>110mmHg). Patients with coronary artery disease (CAD) that have been successfully treated with coronary artery by-pass graft (CABG) or percutaneous coronary intervention (PCI) or are 1 year after implantation of drug eluting stent and have no evidence of active ischemia are eligible.\n5. Known history of chronic liver disease (except for NAFLD\u002FNASH), hepatitis, positive serologic test result for hepatitis B surface antigen and\u002For hepatitis C antibody, alpha-1-antitrypsin deficiency.\n6. Gastrointestinal disorders including a known history of celiac disease and\u002For other malabsorptive disorders or inflammatory bowel disease (Chron's disease or ulcerative colitis).\n7. Psychiatric disorders including dementia, active psychosis, severe depression requiring \\>2 medications, history of suicide attempts, alcohol or drugs abuse with previous 12months.\n8. Pregnancy.\n9. Malignancy within 5 years (except squamous cell and basal cell cancer of skin).\n10. Anaemia defined as haemoglobin less than 9 in females and 10 in males.\n11. Any medical condition requiring anticoagulation therapy that cannot be temporarily discontinued for surgical or embolic approach.\n12. Any condition or major illness that, in the investigator's judgment, places the subject at undue risk by participating in the study.\n13. Use of investigational therapy or participation in any other clinical trial within 12 weeks prior to signing the informed consent form.\n14. Severe pulmonary disease.\n15. American Society of Anesthesiologists (ASA) physical status class IV or higher.\n16. History of allergy to iodinated contrast media","75 Years",{"count":202,"type":21},30,[24],"Obesity and Type 2 diabetes mellitus (DMT2) are two of the most common chronic diseases of the Western society. Obesity is one critical factor in DMT2 development, with weight loss having profound beneficial effects on DMT2 and improving the metabolic pathophysiology leading to hyperglycemia.\n\nObservational studies reported that surgical intervention of morbid obesity achieved significant improvement of resolution of DMT2, both in short and long-term. Bariatric surgery has been considered the best option for treatment of diabetic obese patients, with the laparoscopic Roux-en-Y Gastric Bypass being the gold standard of the surgical treatment. Bariatric arterial embolization (BAE) technique has proved to be safe effective for weight loss in obese patients, but its metabolic effects have not been studied yet. The hypothesis of the study is that BAE is effective for the resolution of DMT2 inpatients with BMI between 30-43 Kg\u002Fm2. The aim is to assess DMT2 remission after BAE and bariatric surgery, to analyze potential conditioning factors, and to compare remission criteria between bariatric surgery and BAE.",[206,207,208,209],"Obesity","Type2diabetes","Bariatric Surgery Candidate","Metabolic Disease",[211,212,213,214,215],"bariatric surgery","embolization","intensive medical therapy","BMI","glycemia","2024-12-10",{"date":218,"type":41},"2024-12-11",{"date":220,"type":41},"2021-06-16",{"date":222,"type":21},"2025-10",{"name":47,"class":48},{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":228,"acronym":229,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":17,"minAge":231,"maxAge":232,"enrollmentInfo":233,"targetDuration":235,"studyType":60,"phases":4,"briefSummary":236,"conditions":237,"keywords":239,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":95},"100543435","intermediate-age-related-macular-degeneration---multimodal-analysis-and-longitudinal-study-100543435","NCT06355830","Intermediate Age-related Macular Degeneration - Multimodal Analysis and Longitudinal Study","Imaging4iAMD","Inclusion Criteria:\n\n* To verify the existence of drusen secondary to intermediate AMD; Soft, cuticular and reticular pseudo-drusen will be considered.\n* Accept and sign the consent.\n\nExclusion Criteria:\n\n* Patients are excluded if it is not possible to obtain good quality CFP, SD-OCT, OCT-A images, if refractive error is ≥±6D or if there is any evidence of accumulation of extracellular fluid, haemorrhage, exudates or fibrosis.\n* Additional exclusion criteria included any history of retinal surgery including laser treatment, signs of diabetic retinopathy, history of retinal vascular occlusion, history of anti-VEGF treatment in the study eye or any signs or history of hereditary retinal or macular dystrophy.","55 Years","95 Years",{"count":234,"type":21},150,"4 Years","Study: observational prospective clinical study. Study population: Subjects over 55 years old with drusen secondary to intermediate AMD.\n\nRecruitment: at the Medical Retinal Consultation from the Ophthalmology Department of CHULC.\n\nPrimary outcome: Identifying imaging predictors of iAMD progression.",[238],"Age-Related Macular Degeneration",[240,241,242,243],"Intermediate AMD","Progression Biomarkers","Late AMD","SD-OCT","2024-04-03",{"date":246,"type":41},"2024-04-09",{"date":248,"type":41},"2019-01-02",{"date":250,"type":21},"2026-06",{"name":47,"class":48},{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":256,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":79,"sex":17,"minAge":130,"maxAge":131,"enrollmentInfo":257,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":258,"conditions":259,"keywords":4,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":267,"locationsCount":95},"100528632","mri-analysis-and-degenerative-spine-100528632","NCT06163300","MRI Analysis and Degenerative Spine",{"count":133,"type":21},"Analysis of MRI advanced techniques in degenerative spinal disease.\n\nThe main questions it aims to answer are:\n\n* Can we assess microstructural integrity of compressed nerve roots in degenerative spinal disease\n* What are the image biomarkers affected by disease\n* How they evolve with disease progression and treatment",[260],"Spine Disease","2024-01-26",{"date":263,"type":41},"2024-01-30",{"date":265,"type":41},"2024-01-01",{"date":122,"type":21},{"name":47,"class":48},{"id":269,"slug":270,"hasResults":11,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":4,"eligibilityCriteria":274,"healthyVolunteers":11,"sex":17,"minAge":130,"maxAge":4,"enrollmentInfo":275,"targetDuration":4,"studyType":22,"phases":277,"briefSummary":278,"conditions":279,"keywords":281,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":4},"100484882","multimorbidity-management-supported-by-a-digital-platform-100484882","NCT05593835","Multimorbidity Management Supported by a Digital Platform","Protocol for a Cluster Randomised Trial of a Goal-Oriented Care Approach for Multimorbidity Patients Supported by a Digital Platform","Inclusion Criteria:\n\n* community-dwelling people\n* aged 50 or older\n* with complex multimorbidity (co-occurrence of three or more chronic conditions affecting three or more different body systems)\n* with access to an Internet connection and a communication technology device\n\nExclusion Criteria:\n\n* inability to: provide informed consent, to read or write, inability to access an email or electronic device, even when helped by an informal caregiver",{"count":276,"type":21},1380,[24],"This study aims to assess whether the use of the METHIS digital platform using a patient-centered approach contributes to an improvement in the quality of life, mental health and physical activity of patients with multimorbidity followed up in Primary Health Care. Practices will be randomly allocated between: providing access to consultations through the METHIS platform (intervention) or following patients by the traditional method (control). They will complete questionnaires on quality of life, mental health and report the number of steps taken, at the beginning and end of the study.",[280],"Chronic Disease",[282,283,284,285,286,287,288],"Primary Health Care","Information Management","Research Design","Telemedicine","Digital Health","Patient-Centered Care","Goal-Oriented Care","2023-11-28",{"date":291,"type":41},"2023-11-29",{"date":293,"type":21},"2025-06-01",{"date":295,"type":21},"2027-05-31",{"name":47,"class":48},""]